ストックスクリーナーアプリを入手
5.945
14.46%
-1.005
前日終値:
$6.95
開ける：
$6.97
24時間の取引高:
2.07M
Relative Volume:
1.58
時価総額：
$280.81M
収益：
$124.00K
当期純損益:
$-49.99M
株価収益率:
-3.5178
EPS:
-1.69
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
-26.24%
1か月 パフォーマンス:
-30.87%
6か月 パフォーマンス:
-17.55%
1年 パフォーマンス:
+276.27%
1日の値動き範囲:
$5.905
$6.97
1週間の範囲:
$5.905
$8.69
52週間の値動き範囲:
$1.56
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.945 | 280.81M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-20 | 開始されました | Citigroup | Buy |
| 2025-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-07 | 開始されました | BofA Securities | Buy |
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive Investors USA
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive Investors USA
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - Stock Traders Daily
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - Marketscreener.com
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors UK
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - Marketscreener.com
Candel Therapeutics Reports Both Prolonged Median Overall - GlobeNewswire
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - StockTitan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive Investors Australia
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel therapeutics CEO sells $229,624 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors UK
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors UK
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - Marketscreener.com
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - StockTitan
Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa
Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com
Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive Investors USA
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times
Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire
Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com India
When (CADL) Moves Investors should Listen - Stock Traders Daily
Candel Therapeutics Reports Positive Clinical Trial Results - TipRanks
Candel Therapeutics (CADL) Receives a Buy from Bank of America Securities - The Globe and Mail
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline - Proactive Investors USA
Candel Therapeutics, Inc. SEC 10-K Report - TradingView
Candel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110 - Nasdaq
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Candel's Breakthrough: Phase 3 Trial Shows 30% Cancer Risk Reduction, Extends Survival 2.5x - StockTitan
Small cap wrap: Fineqia, Ocean Power Technologies, NEXE Innovations... - Proactive Investors UK
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Acquired by Rhumbline Advisers - Defense World
Oppenheimer & Co. Inc. Purchases Shares of 37,915 Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
(CADL) Technical Data - Stock Traders Daily
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
Candel Therapeutics Inc (CADL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Mar 18 '25 |
Sale |
8.76 |
45,316 |
396,995 |
52,493 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Option Exercise |
1.55 |
18,000 |
27,900 |
128,673 |
| Barone Francesca | Chief Scientific Officer |
Mar 18 '25 |
Sale |
8.76 |
32,146 |
281,673 |
96,527 |
| Tak Paul Peter | Chief Executive Officer |
Mar 18 '25 |
Sale |
8.77 |
25,772 |
226,023 |
226,140 |
| Tak Paul Peter | Chief Executive Officer |
Mar 19 '25 |
Sale |
9.00 |
400 |
3,601 |
225,740 |
| Tyagarajan Seshu | Chief Technology Officer |
Mar 17 '25 |
Sale |
8.82 |
31,278 |
275,947 |
85,512 |
| Schoch Charles | See Remarks |
Mar 17 '25 |
Sale |
8.83 |
5,000 |
44,169 |
38,038 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):